Case Study: Outsourced Sales Team Yields 7:1 ROI
Amplity Health showcased a case study for a rare disease product launch where an outsourced, remote sales team achieved a 7:1 return on investment within 30 days. The result was driven by targeted engagement with healthcare professionals. The case highlights the potential effectiveness of specialized, outsourced sales models in the pharmaceutical sector.
The high return on investment was driven by a proprietary data platform, known as AnswerY, which allowed the remote team to identify healthcare providers treating patients with specific, intersecting symptoms suggestive of the rare disease. This data-driven approach bypassed reliance on traditional claims data, uncovering prescribers and patients who would have otherwise been missed. In one neurology rare disease launch, this strategy resulted in 63 new patient starts by the end of the first year and a 13:1 ROI, while also reducing the client's field team footprint by 15 representatives for a 30% cost savings. Another similar initiative for a pediatric rare disease therapy fueled a $7 million launch success in its first quarter. This specialized model is particularly effective for rare diseases due to unique market challenges, including small, geographically dispersed patient populations and complex, delayed diagnostic journeys that traditional sales models struggle to address. These launches often require deep therapeutic expertise and the flexibility to scale operations up or down quickly, which outsourcing provides. The broader pharmaceutical industry is increasingly outsourcing its commercial activities, with the global market for contract sales organizations (CSO) valued at approximately $11 billion and projected to reach $12 billion in 2026. This trend is driven by rising drug development costs and the need for specialized expertise, particularly for complex new therapies. The 30-day ROI stands in sharp contrast to typical enterprise sales cycles in healthcare, which often last from 6 to over 24 months due to the involvement of multiple stakeholders and strict compliance reviews. Amid current budget pressures, 58% of healthcare buyers are shifting focus to purchases that can demonstrate a return on investment within 12 months or less. This rapid, targeted approach serves as a competitive displacement strategy against incumbent vendors. Dominant players can be slow to adapt, creating opportunities for agile teams that use precise data to identify and solve specific clinical or financial pain points, thereby creating urgency and accelerating the deal cycle.
